Novartis C.E.O. Defends Company’s Decision to Withhold False Data From the F.D.A.

Responding to the agency’s stern rebuke, Vas Narasimhan, the company’s executive, tried to reassure investors that Novartis did not intentionally deceive the F.D.A. while seeking approval for its $2.1 million gene therapy.
By KATIE THOMAS from NYT Health https://ift.tt/2YPZ7N5
via IFTTT
Falsification of Data, Drugs (Pharmaceuticals), Genetic Engineering
Source The New York Times
Làm đẹp Blog 247